公开(公告)号：US09738710B2

公开(公告)日：2017-08-22

申请号：US14547291

申请日：2014-11-19

Applicant: UCB Biopharma SPRL

Inventor： Karen Margrete Miller ,  Marc Roger De Ryck ,  Christian Gilbert J. Wolff ,  Alastair David Griffiths Lawson ,  Helene Margaret Finney ,  Terence Seward Baker

IPC: A61K39/395 ,  C12P21/08 ,  C07K16/00 ,  C07K16/28 ,  A61K39/00 ,  C07K16/18

CPC classification number: C07K16/18 ,  C07K16/28 ,  C07K2317/34

Abstract: An anti-E1 ion channel antibody or binding fragment thereof, pharmaceutical compositions comprising said antibodies, use of the antibodies and compositions comprising the same, in treatment, for example in the treatment/modulation of pain and processes for generating and preparing said antibodies.

公开(公告)号：US20170140118A1

公开(公告)日：2017-05-18

申请号：US14945070

申请日：2015-11-18

Applicant: UCB BIOPHARMA SPRL

Inventor： Nassim HADDAD ,  Arnaud LIEUTENANT ,  Thomas FILAIRE

IPC: G06F19/00 ,  G06F3/0486 ,  G06F3/0484

CPC classification number: G16H40/63 ,  G06F3/04847 ,  G06F3/0486 ,  G06F19/3418 ,  G16H50/70

Abstract: A computerized method for displaying categorized healthcare textual data after a taxonomy has been applied to a data set is provided. The method includes generating a visual network generator graphical user interface configured to display a visual network comprised of a plurality of nodes and links, each of the nodes corresponding to a healthcare treatment topic, each of the links connecting two of the nodes; receiving a nodes input delimiting a number of the nodes to be displayed in the visual network; receiving at least one links input delimiting the links to be displayed in the visual network, the at least one links input including a first link input delimiting the links based on a modifiable metric representing a mixture of a first metric and a second metric, the first metric indicating a strength of potential links of each of the topics represented by one of the delimited nodes in the data set with each of the topics represented by the other delimited nodes of the data set, the second metric indicating a strength of each of the potential links of the delimited nodes in comparison to other potential links of the two respective delimited nodes each of the potential links is connecting; and generating, in response to the nodes input and the at least one links input, the delimited nodes and the delimited links in the visual network on the visual network generator graphical user interface to illustrate correlations between the healthcare treatment topics of different categories.

公开(公告)号：US20170140110A1

公开(公告)日：2017-05-18

申请号：US14945082

申请日：2015-11-18

Applicant: UCB BIOPHARMA SPRL

Inventor： Nassim HADDAD ,  Arnaud LIEUTENANT ,  Thomas FILAIRE

IPC: G06F19/00 ,  G06K9/00 ,  G06F17/30 ,  G06F3/0484

CPC classification number: G06F19/326 ,  G06F3/04847 ,  G06F16/2465 ,  G06F16/338 ,  G06F16/358 ,  G06K9/00456

Abstract: A computerized method for generating and displaying structured topics of a taxonomy in different formats is provided. The computerized method includes generating a categorized topic viewer graphical user interface allowing a user to select a textual model defining a corpus of documents to explore by delimiting a healthcare treatment product; generating in the categorized topic viewer graphical user interface, in response to an input of the user delimiting the healthcare treatment product, at least one of a plurality of tools; generating in a topic mapping graphical user interface an interactive map illustrating the number of documents for a first class for each corresponding country; generating in a trend generating graphical user interface at least one of a plurality of tools; and modifying each of the categorized topic viewer graphical user interface, the topic mapping graphical user interface and the trend generating graphical user interface in response to at least one input of the user into at least one taxonomy filter such that data displayed by each of the categorized topic viewer graphical user interface, the topic mapping graphical user interface and the trend generating graphical user interface display data related to a second class of the corpus of documents, the second class being a subcategory of the first class.

公开(公告)号：US20170129905A1

公开(公告)日：2017-05-11

申请号：US15318422

申请日：2015-06-11

Applicant: UCB Biopharma SPRL ,  Katholieke Universiteit Leuven, K.U.Leuven R&D

Inventor： Daniel James Ford ,  Qiuya Huang ,  Judi Charlotte Neuss ,  James Thomas Reuberson ,  Bart Vanderhoydonck

IPC: C07D498/04 ,  C07D487/04 ,  C07D495/04

CPC classification number: C07D498/04 ,  A61K31/519 ,  C07D487/04 ,  C07D495/04

Abstract: A series of fused bicyclic heteroaromatic derivatives of formula (IA) or (IB), as defined herein, being selective inhibitors of phosphatidylinositol-4-kinase IIIβ (PI4KIIIβ) activity, are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases and malaria; and organ and cell transplant rejection.

公开(公告)号：US20160376275A1

公开(公告)日：2016-12-29

申请号：US15038733

申请日：2014-12-08

Applicant: UCB Biopharma SPRL

Inventor： Mezher Hussein ALI ,  Daniel Christopher BROOKINGS ,  Julien Alistair BROWN ,  Martin Clive HUTCHINGS ,  Victoria Elizabeth JACKSON ,  Boris KROEPLIEN ,  John Robert PORTER ,  Joanna Rachel QUINCEY

IPC: C07D487/04 ,  A61K31/5377 ,  A61K31/506 ,  A61K31/5025

CPC classification number: C07D487/04 ,  A61K31/5025 ,  A61K31/506 ,  A61K31/5377

Abstract: A series of substituted imidazo[1,2-b]pyridazine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract translation: 因此，作为人类TNFα活性的有效调节剂的一系列取代的式（I）咪唑并[1,2-b]哒嗪衍生物因此有益于治疗和/或预防各种人类疾病，包括自身免疫性和炎症性疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。

公开(公告)号：US20160355509A1

公开(公告)日：2016-12-08

申请号：US15038555

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Victoria Elizabeth Jackson ,  Boris Kroeplien ,  John Robert Porter

IPC: C07D471/04 ,  A61K31/444 ,  A61K31/437

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/444

Abstract: A series of substituted 3H-imidazo[4,5-c]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract translation: 因此，作为人类TNFα活性的有效调节剂的一系列取代的式（I）的3H-咪唑并[4,5-c]吡啶衍生物因此有益于治疗和/或预防各种人类疾病，包括自身免疫和炎症 疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。

公开(公告)号：US09499603B2

公开(公告)日：2016-11-22

申请号：US14802076

申请日：2015-07-17

Applicant: UCB Biopharma SPRL

Inventor： Kerry Louise Tyson

IPC: C07K16/00 ,  C07K14/705 ,  C07K16/28

CPC classification number: C07K14/70503 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/73 ,  C07K2317/75 ,  C07K2317/92

Abstract: A humanised agonistic antibody which binds human PD-1 comprising a heavy chain and a light chain wherein the variable domain of the heavy chain comprises the sequence given in SEQ ID NO:1 for CDR-H1, the sequence given in SEQ ID NO:2 for CDR-H2 and the sequence given in SEQ ID NO:3 for CDR-H3 and the variable domain of the light chain comprises the sequence given in SEQ ID NO:4 for CDR-L1, the sequence given in SEQ ID NO:5 for CDR-L2 and the sequence given in SEQ ID NO:7 for CDR-L3. The invention also extends to therapeutic uses of the antibody molecules, compositions and methods for producing said antibody molecules.

公开(公告)号：US20160304513A1

公开(公告)日：2016-10-20

申请号：US15101089

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Michael Louis Robert Deligny ,  Jag Paul Heer ,  Victoria Elizabeth Jackson ,  Boris Kroeplien ,  Fabien Claude Lecomte ,  John Robert Porter

IPC: C07D471/04 ,  A61K31/506 ,  A61K31/437

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/506

Abstract: A series of substituted 3H imidazo[4,5-b]pyridine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

公开(公告)号：US20160304512A1

公开(公告)日：2016-10-20

申请号：US15101044

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Daniel Christopher Brookings ,  Victoria Elizabeth Jackson

IPC: C07D471/04 ,  A61K31/506 ,  A61K31/437 ,  A61K31/5377

CPC classification number: C07D471/04 ,  A61K31/437 ,  A61K31/506 ,  A61K31/5377

Abstract: A series of substituted [1,2,4]triazolo[4,3-a]pyridine derivatives, being potent modulators of human TNF activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.

Abstract translation: 因此，作为人类TNF活性的有效调节剂的一系列取代的[1,2,4]三唑并[4,3-a]吡啶衍生物在治疗和/或预防各种人类疾病中是有益的，包括自身免疫和炎症 疾病; 神经和神经退行性疾病; 疼痛和伤害性疾病; 心血管疾病; 代谢紊乱 眼部疾病; 和肿瘤疾病。

公开(公告)号：US20160297827A1

公开(公告)日：2016-10-13

申请号：US15100690

申请日：2014-12-08

Applicant: UCB BIOPHARMA SPRL

Inventor： Mezher Hussein Ali ,  Daniel Christopher Brookings ,  Julien Alistair Brown ,  Victoria Elizabeth Jackson ,  Boris Kroeplien ,  John Robert Porter

IPC: C07D487/04 ,  A61K31/5377 ,  A61K31/519

CPC classification number: C07D487/04 ,  A61K31/519 ,  A61K31/5377

Abstract: A series of substituted imidazo[1,2-a]pyrimidine derivatives of formula (I), being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.